

ACTA MEDICINAE 6/2012 FARMAKOLOGIE

Kompletní literatura

- 2 **Stoupající odolnost bakterií k antibiotikům – výzva pro farmakoterapii 21. století**
prof. MUDr. Milan Kolář, Ph.D. Ústav mikrobiologie FN a LF UP v Olomouci
- 2 **Denosumab v léčbě postmenopauzální osteoporózy**
prof. MUDr. Pavel Horák, CSc. III. interní klinika – nefrologická, revmatologická, endokrinologická, FN a LF UP v Olomouci
- 3 **Kombinační terapie hypertenze, fixní kombinace perindoprilu a indapamidu**
prof. MUDr. Hana Rosolová, DrSc. Centrum preventivní kardiologie, 2. interní klinika LF UK a FN Plzeň
- 4 **Novinky v antikoncepční farmakoterapii**
MUDr. Daniel Driák, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a Nemocnice Na Bulovce, Praha
- 5 **Kombinovaná léčba hepatitidy C telaprevirem a peginterferonem alfa a ribavirinem**
prof. MUDr. Petr Husa, CSc. Klinika infekčních chorob LF Masarykovy univerzity a FN Brno
- 5 **Adherence k léčbě interferonem β -1a**
MUDr. Pavel Hradílek, Ph.D. MS centrum, Neurologická klinika FN Ostrava
- 6 **Gilena, perorální farmakoterapie roztroušené sklerózy**
doc. MUDr. Jan Mareš, Ph.D. Centrum pro diagnostiku a léčbu demyelinizačních onemocnění, Neurologická klinika LF UP a FN, Olomouc
- 6 **Léčba hypertenze fixní kombinací amlodipinu a bisoprololu**
MUDr. Jiří Slíva, Ph.D. Ústavy farmakologie 2. a 3. LF UK, Praha
- 6 **Octreotid v léčbě průjmů vyvolaných cytostatiky**
MUDr. Oldřich Louthan IV. interní klinika, Centrum pro neuroendokrinní nádory, VFN a 1. LF UK, Praha
- 7 **Nové možnosti léčby CHOPN selektivním inhibítorem fosfodiesterázy 4 (PDE4) roflumilastem – kazuistika**
MUDr. Zuzana Perná Pneumologická ambulance Medicon, a. s., Praha
- 7 **Symptomatická léčba Alzheimerovy demence – využití rivastigminu**
doc. MUDr. Roman Jiráček, CSc. Psychiatrická klinika 1. LF UK a VFN Praha
- 8 **Endometrióza – diagnostika a terapie, nové metody**
MUDr. Pavel Tomeš | doc. MUDr. Zdeněk Novotný, CSc. Gynekologicko-porodnická klinika LF UK a FN Plzeň
- 8 **Reprogramace terminálně diferencovaných buněk**
prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

Stoupající odolnost bakterií k antibiotikům – výzva pro farmakoterapii 21. století

prof. MUDr. Milan Kolář, Ph.D. Ústav mikrobiologie FN a LF UP v Olomouci

- 1 Hanulík, V. – Uvzl, R. – Husičková, V. – Htoutou Sedláková, M. – Kolář, M.: Bakteriální původci pneumonií u pacientů v intenzivní péči. *Klin Mikrobiol Inf Lék*, 2011, 17, s. 134–139.
- 2 Alberti, C. – Brun-Buisson, C. – Burchardi, H., et al.: Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. *Intensive Care Med*, 2002, 28, s. 108–121.
- 3 Arnan, M. – Gudiol, C. – Calatayud, L., et al.: Risk factors for, and clinical relevance of, faecal extended-spectrum β -lactamase producing *Escherichia coli* (ESBL-EC) carriage in neutropenic patients with haematological malignancies. *Eur J Clin Microbiol Infect Dis*, 2011, 30, s. 335–360.
- 4 Viscoli, C.: EORTC International Antimicrobial Therapy Group. Management of infection in cancer patients. Studies of the EORTC International Antimicrobial Therapy Group (IATG). *Eur J Cancer*, 2002, 38 (dopl. 4), s. 82–87.
- 5 Mikulska, M. – Del Bono, V. – Raiola, A. M., et al.: Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: re-emergence of Gram-negative rods and increasing antibiotic resistance. *Biol Blood Marrow Transplant*, 2009, 15, s. 47–53.
- 6 Cattaneo, C. – Quaresmini, G. – Casari, S., et al.: Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant *Escherichia coli* among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. *J Antimicrob Chemother*, 2008, 61, s. 721–728.
- 7 Kolář, M. – Htoutou Sedláková, M. – Hanulík, V., et al.: Multirezistentní gramnegativní bakterie u hematologických nemocných. *Postgrad Med*, 2012, v tisku.
- 8 Neu, H. C.: The crisis in antibiotic resistance. *Science*, 1992, 257, s. 1064–1073.
- 9 Kolář, M. – Urbánek, K. – Látal, T.: Antibiotic selection pressure and development of bacterial resistance. *Intern J Antimicrob Agents*, 2001, 17, s. 357–363.
- 10 Urbánek, K. – Kolář, M. – Lovečková, Y., et al.: Influence of 3rd generation cephalosporin utilization on the occurrence of ESBL-positive *Klebsiella pneumoniae* strains. *J Clin Pharm Ther*, 2007, 32, s. 403–408.
- 11 Htoutou Sedláková, M. – Vojtová, V. – Hanulík, V. – Suchánková, H. – Kolář, M.: Rezistence enterobakterií k vybraným antibiotikům v souvislosti s jejich spotřebou. *Klin Farmakol Farmacie*, 2012, 26, s. 61–66.
- 12 Adensko, A. – Alvarez-Espejo, T. – Fernandes-Crehuet, J., et al.: On behalf of the Estudio de Prevalencia de las Infecciones Nosocomiales en España (EPINE) Working Group. Trends in yearly prevalence of third-generation cephalosporin and fluoroquinolone resistant Enterobacteriaceae infections and antimicrobial use in Spanish hospitals, Spain, 1999 to 2010. *Euro Surveill*, 2011, 16, pii=19983.
- 13 Bosso, J. A. – Mauldin, P. D. – Salgado, C. D.: The association between antibiotic use and resistance: the role of secondary antibiotics. *Eur J Clin Microbiol Infect Dis*, 2010, 29, s. 1125–1129.
- 14 Kesselová, M. – Kolář, M. – Sauer, P., et al.: Molekulárně-biologická analýza ESBL-pozitivních kmenů *Klebsiella pneumoniae* na novorozeneckém oddělení Fakultní nemocnice Olomouc. *Klin Mikrobiol Inf Lék*, 2005, 11, s. 20–24.
- 15 Chroma, M. – Kolar, M.: Genetic methods for detection of antibiotic resistance: focus on extended-spectrum β -lactamases. *Biomed Papers*, 2010, 154, s. 289–296.
- 16 Luna, C. M. – Vujacich, P. – Niederman, M. S., et al.: Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. *Chest*, 1997, 111, s. 676–685.
- 17 Micek, S. T. – Lloyd, A. E. – Ritchie, D. J., et al.: *Pseudomonas aeruginosa* bloodstream infection: importance of appropriate initial antimicrobial treatment. *Antimicrob Agents Chemother*, 2005, 49, s. 1306–1311.
- 18 Trecarichi, E. M. – Tubarello, M. – Caira, M., et al.: Multidrug resistant *Pseudomonas aeruginosa* bloodstream infection in adult patients with hematological malignancies. *Hematologica*, 2011, 96, s. e1–3.
- 19 Rello, J. – Torres, A. – Ricart, M., et al.: Ventilator-associated pneumonia by *Staphylococcus aureus*. Comparison of methicillin-resistant and methicillin-sensitive episodes. *Am J Respir Crit Care Med*, 1994, 150, s. 1545–1549.
- 20 Kumar, A. – Roberts, D. – Wood, K. E., et al.: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. *Crit Care Med*, 2006, 34, s. 1589–1596.
- 21 Kolář, M.: Volba antibiotik v intenzivní péči. *Postgrad Med*, 2012, 14, s. 510–513.

Denosumab v léčbě postmenopauzální osteoporózy

prof. MUDr. Pavel Horák, CSc.

III. interní klinika – nefrologická, revmatologická, endokrinologická, FN a LF UP v Olomouci

- 1 Riggs, B. L. – Melton, L. J.: The worldwide problem of osteoporosis, insights afforded by epidemiology. *Bone*, 1995, 17 (dopl.), s. 505–511.
- 2 American Stroke Association. Heart disease and stroke statistics–2005 update. Dostupné na: www.americanheart.org/downloadable/heart/.
- 3 American Cancer Society. Cancer facts & figures, 2005. Dostupné na: www.cancer.org/downloads/ST.
- 4 Cauley, J. A. – Thompson, D. E. – Ensurd, K. S., et al.: Risk of mortality following clinical fractures. *Osteoporosis Int*, 2000, 11, s. 556–561.
- 5 Lewiecki, E. M.: RANK ligand inhibition with denosumab for the management of osteoporosis. *Exper Opin Biol Ther*, 2006, 6, s. 1041–1050.
- 6 McClung, M. R. – Lewiecki, E. M. – Cohen, S. B., et al.: Denosumab in postmenopausal women with low bone mineral density. *N Engl J Med*, 2006, 354, s. 821–831.
- 7 Hsu, H. – Lacey, D. L. – Dunstan, C. R., et al.: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. *Proc Natl Acad Sci U S A*, 1999, 96, s. 3540–3545.
- 8 Fata, J. K. – Kong, Y. Y. – Li, J., et al.: The osteoclast differentiation factor osteoprotegerin ligand is essential for mammary gland development. *Cell*, 2000, 103, s. 41–50.
- 9 Anderson, D. M. – Maraskovsky, E. – Billingsley, W. L., et al.: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. *Nature*, 1997, 390, s. 175–179.
- 10 Boyle, W. J. – Simonet, W. S. – Lacey, D. L., et al.: Osteoclast differentiation and activation. *Nature*, 2003, 423, s. 337–342.
- 11 Bekker, P. J. – Holloway, D. L. – Rasmussen, A. S., et al.: Single-dose

- placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. *J Bone Miner Res*, 2004, 19, s. 1059–1066.
- 12 Yasuda, H. – Shima, N. – Nakagawa, N., et al.: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis inhibitory factor and is identical to TRANCE/RANKL. *Proc Natl Acad Sci U S A*, 1998, 95, s. 3597–3602.
 - 13 Lacey, D. L. – Tan, H. L. – Lu, J., et al.: Osteoprotegerin Ligand Modulates Murine Osteoclast Survival in Vitro and in Vivo. *Am J Pathol*, 2000, 157, s. 435–448.
 - 14 Lewiecki, E. M. – Miller, P. D. – McClung, M. R., et al.: Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. *J Bone Miner Res*, 2007, 22, s. 1832–1841.
 - 15 Miller, P. D. – Wagman, R. B. – Peacock, M., et al.: Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year results of Phase 2 Clinical Trial. *J Clin Endocrinol Metab*, 2011, 96, s. 394–402.
 - 16 Bone, H. G. – Bolognese, M. A. – Yuen, C. K., et al.: Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. *J Clin Endocrinol Metab*, 2008, 93, s. 2149–2157.
 - 17 Brown, J. P. – Prince, R. L. – Deal, C., et al.: Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial. *J Bone Miner Res*, 2009, 24, s. 153–161.
 - 18 Kendler, D. I. – Roux, C. – Benhamou, C. L., et al.: Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. *J Bone Miner Res*, 2010, 25, s. 72–81.
 - 19 Cummings, S. R. – San Martin, J. – McClung, M. R., et al.: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. *N Engl J Med*, 2009, 361, s. 756–765.
 - 20 Li, Z. – Chines, A. A. – Meredith, M. P.: Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture? *J Musculoskelet Neuronal Interact*, 2004, 4, s. 64–74.
 - 21 Cummings, S. – Yang, Y. – Vittinghoff E, et al.: Increases in BMD on denosumab explain much of the reduction in fracture risk. *J Bone Miner Res*, 2009, 24 (dopl. 1), s. 56.
 - 22 Brown, J. P. – Bone, H. G. – Chapurlat, R., et al.: Six years of denosumab treatment in postmenopausal women with osteoporosis: results from the first three years of the FREEDOM extension. Prezentováno na American College of Rheumatology Annual Scientific Meeting, 8. listopadu 2011, Chicago.
 - 23 Dempster, D. W.: *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*. 2006, s. 7–11.
 - 24 Seeman, E. – Delmas, P. D.: Bone quality — the material and structural basis of bone strength and fragility. *N Engl J Med*, 2006, 354, s. 2250–2261.
 - 25 Hologic, Inc.: Emerging trends in dual energy x-ray absorptiometry. www.hologic.com/sh/pdf/W_159_09-06_%20EmergTrendinDXA.pdf, vyhledáno 20. listopadu 2010.
 - 26 Beck, T. J.: Extending DXA beyond bone mineral density: understanding hip structure analysis. *Curr Osteoporos Rep*, 2007, 5, s. 49–55.
 - 27 Beck, T. J. – Lewiecki, E. M. – Miller, P. D., et al.: Effects of denosumab on the geometry of the produmal lemur in postmenopausal women in comparison with alendronate. *J Clin Densitom*, 2008, 11, s. 351–359.
 - 28 Genant, H. K. – Engelke, K. – Hanley, D. A., et al.: Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. *Bone*, 2010, 47, s. 131–139.
 - 29 Keaveny, T. – McClung, M. R. – Genant, H. K., et al.: Denosumab improves both femoral and vertebral strength in women with osteoporosis: Results from the FREEDOM Trial. ASBMR annual meeting 2010; Kniha Abstrakt, S31, Abstrakt č. 1099.
 - 30 Reid, I. R. – Miller, P. D. – Brown, J. P., et al.: Effects of Denosumab on Bone Histomorphometry: The FREEDOM and STAND Studies. *J Bone Miner Res*, 2010, 25, s. 2256–2265.
 - 31 Gever, J.: FDA questions denosumab safety in advisory meeting documents. Dostupné na: www.medpagetoday.com/ProductAlert/Prescriptions/15486, vyhledáno 20. listopadu 2010.
 - 32 Lewiecki, E. M.: Treatment of osteoporosis with denosumab. *Maturitas*, 2010, 66, s. 182–186.

Kombinační terapie hypertenze, fixní kombinace perindoprilu a indapamidu

prof. MUDr. Hana Rosolová, DrSc.

Centrum preventivní kardiologie, 2. interní klinika LF UK a FN Plzeň

- 1 Kotseva, K. – Wood, D. – De Backer, G., et al.: EUROASPIRE III: A survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from twenty-two European countries. *Eur J Cardiovasc Prev Rehabil*, 2009; doi: 10.1097/HJR.0b013e3283294b1d.
- 2 Wald, D. S. – Law, M. – Morris, J. K., et al.: Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. *Am J Med*, 2009, 122 (3), s. 290–300.
- 3 Dahlhof, B. – Sever, P. S. – Poulter, N. R., et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomized controlled trial. *Lancet*, 2005, 366, s. 1–2.
- 4 Bakris, G. – Molitch, M. – Hewkin, A., et al.: Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. *Diabetes Care*, 2006, 29, s. 2592–2597.
- 5 ADVANCE Collaborative Group: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial). *Lancet*, 2007, 370, s. 829–840.
- 6 Dahlöf, B. – Gosse, P. – Guéret, P., et al.: Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. *J Hypertens*, 2005, 23, s. 2063–2070.
- 7 Mogensen, C. E. – Viberti, G. – Halimi, S., et al.: Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. *Hypertension*, 2003, 41, s. 1063–1071.
- 8 Mourad, J. J. – Hanon, O. – Devereux, J. R., et al.: Improvement of impaired coronary vasodilator reserve in hypertensive patients by low-dose ACE inhibitor/diuretic therapy: a pilot PET study. *J Renin Angiotensin Aldosterone Syst*, 2003, 4, s. 94–95.
- 9 Levy, B. I. – Ambrosio, G. – Pries, A. R., et al.: Microcirculation in hypertension: a new target for treatment? *Circulation*, 2001, 104, s. 735–740.
- 10 Laurent, S. – Briet, M. – Boutouyrie, P.: Large and small artery cross-talk and recent morbidity – mortality trials in hypertension. *Hypertension*, 2009, 54, s. 388–392.

Novinky v antikoncepční farmakoterapii

MUDr. Daniel Driák, Ph.D.

Gynekologicko-porodnická klinika 1. LF UK a Nemocnice Na Bulovce, Praha

- 1 **Mansour, D.:** *Unintended pregnancies as a global health issue: is there a role for long-acting reversible contraceptives?* 12. kongres Evropské společnosti pro kontracepci a reprodukční zdraví, Athény, červen 2012, přednáška.
- 2 **Zhang, L. Y. – Jejeebhoy, S. – Shah, I. H., et al.:** Access to contraceptive services among unmarried young people in the north-east of China. *Eur J Contracept Reprod Health Care*, 2004, 9 (3), s. 147–154.
- 3 **Zvěřina, J.:** *Sexuologie (nejen) pro lékaře*. Brno, Akademické nakladatelství CERM, 2003, s. 288.
- 4 **Jilich, D.:** *Problematika HIV pozitivních žen v ČR*. 4. konference Sekce infekčních nemocí v gynekologii a porodnictví ČGPS ČLS JEP. Praha, listopad, 2011, přednáška.
- 5 **Gupta, G.:** Microbicidal spermicide or spermicidal microbicide? *Eur J Contracept Reprod Health Care*, 2005, 10 (4), s. 212–218.
- 6 **Mauck, Ch. – Callahan, M. – Weiner, D., et al.:** A comparative study of the safety and efficacy of FemCap, a new vaginal barrier contraceptive, and the Ortho All-Flex Diaphragm. *Contracept*, 1999, 60, s. 71–80.
- 7 **Yedery, R. D. – Reddy, K. V. R.:** Antimicrobial peptides as microbical contraceptives: prophecies for prophylactics – a mini review. *Eur J Contracept Reprod Health Care*, 2005, 10 (1), s. 32–42.
- 8 **Skouby, S. O.:** Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. *Eur J Contracept Reprod Health Care*, 2004, 9 (2), s. 57–68.
- 9 **Čepický, P. – Dvořák, K. – Holub, Z., et al.:** Kombinovaná perorální kontracepce s extrémně nízkou dávkou estrogenu (15 µg v jedné tabletě). *Čes Gynek*, 2001, 66 (4), s. 297–299.
- 10 **Schwenhagen, A.:** *Combined oral contraceptives with estradiol: will reality live up to expectations?* 12. kongres Evropské společnosti pro kontracepci a reprodukční zdraví, Athény, červen 2012, přednáška.
- 11 **Čepický, P.:** Kombinovaná hormonální antikoncepce. *Mod Gynek Porod*, 2004, 13 (4), 4, s. 585–620.
- 12 **Rowlands, S.:** Newer progestogens. *J Fam Plann Reprod Health Care*, 2003, 29 (1), s. 13–16.
- 13 **Sitruk-Ware, R.:** Pharmaceutical profile of progestins. *Maturitas*, 2004, 47 (4), s. 277–283.
- 14 **Read, C. M.:** New regimens with combined oral contraceptive pills – moving away from traditional 21/7. *Eur J Contracept Reprod Health Care*, 2010, 15 (dopl. 2), s. S32–S41.
- 15 **Adams Hillard, P. J.:** Kdy je vhodné indukovat amenoreu? Komentář: Čepický, P. *Gynek po prom*, 2003, 3 (6), s. 30–38.
- 16 **Kaunitz, A. M.:** Menstruace je věcí volby. Komentář: Strnad, P. *Gynek po prom*, 2001, 1 (5), s. 19–25.
- 17 **Mansbach, J. M. – Emans, S.:** Praktické rady pro předepisování hormonální antikoncepce mladistvým. Komentář: Teslík, L. *Gynek po prom*, 2002, 2 (4), s. 25–34.
- 18 **Cibula, D.:** Kontinuální schéma užívání – významný trend v kombinované hormonální kontracepci. *Čes Gynek*, 2006, 71 (1), s. 66–69.
- 19 **Skouby, S. O.:** *Oral estradiol versus ethinyl-estradiol: risks and benefits*. 12. kongres Evropské společnosti pro kontracepci a reprodukční zdraví, Athény, červen 2012, přednáška.
- 20 **Slíva, J.:** Přirozené a syntetické estrogény v hormonální antikoncepci. *Gynekolog*, 2009, 18 (2), s. 58–61.
- 21 **Calaf i Alsina, J.:** After 50 years of ethinylestradiol, another oestrogen in combined oral contraceptives. *Eur J Contracept Reprod Health Care*, 2010, 15, dopl. 2, s. S9–S11.
- 22 **Mansour, D.:** *Qlaira in the treatment of heavy menstrual bleeding*. 12. kongres Evropské společnosti pro kontracepci a reprodukční zdraví, Athény, červen 2012, přednáška.
- 23 **Skouby, S. O.:** *Estetrol: a new fetal human estrogen with unique properties*. 12. kongres Evropské společnosti pro kontracepci a reprodukční zdraví, Athény, červen 2012, přednáška.
- 24 **Visser, M. – Coelingh Bennink, H. J.:** Clinical applications for estetrol. *J Steroid Biochem Mol Biol*, 2009, 114 (1–2), s. 85–89.
- 25 **Cibula, D.:** *Contraception in cancer prevention*. 12. kongres Evropské společnosti pro kontracepci a reprodukční zdraví, Athény, červen 2012, přednáška.
- 26 www.sukl.cz.
- 27 **Cronin, M. – Schellschmidt, I. – Dinger, J.:** Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives. *Obstet Gynecol*, 2009, 114 (3), s. 616–622.
- 28 **Čepický, P. – Cibula, D. – Dvořák, K., et al.:** Doporučení k předpisu gestagenní kontracepce. Aktualizace 2006. *Čes Gynek*, 2006, 71 (5), s. 421–423.
- 29 **Unzeitig, V.:** Profil uživatelky pilulky Cerazette. *Mod Gynek Porod*, 2005, 14 (2), dopl., s. 312–315.
- 30 **Bouchard, P. – Chabbert-Buffet, N. – Fauser, B. C. J. M.:** Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. *Fertil Steril*, 2011, 96, s. 1175–1189.
- 31 **Chabbert-Buffet, N. – Ouzounian, S. – Kairis, A. P., et al.:** Contraceptive applications of progesterone receptor modulators. *Eur J Contracept Reprod Health Care*, 2008, 13 (3), s. 222–230.
- 32 **Chabbert-Buffet, N.:** Selective progesterone receptor modulators. *Eur J Contracept Reprod Health Care*, 2010, 15, dopl. 1, s. 7–8.
- 33 **McKeage, K. – Croxtall, J. D.:** Ulipristal acetate: a review of its use in emergency contraception. *Drugs*, 2011, 71 (7), s. 935–945.
- 34 **Scott, L. J. – McKeage, K. – Croxtall, J. D.:** Ulipristal acetate: a guide to its use in emergency contraception. *Drugs Ther Perspect*, 2012, 28 (2), s. 6–9.
- 35 **Ramalho-Santos, J. – Baptista, M.:** Modulating sperm function for contraception: a multilayered challenge. *Eur J Contracept Reprod Health Care*, 2012, 17 (dopl. 1), s. S6.
- 36 **Cone, R. A. – Hoen, T. – Wong, X., et al.:** Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission. *BMC Infect Dis*, 2006, 6, s. 90.
- 37 **Aktualizace doporučených postupů CDC pro léčbu pohlavně přenosných chorob.** Komentář: Čepický, P., *Gynek po prom*, 2003, 3 (1), s. 32–40.
- 38 **Ingram, M. J. – Zeller, E. – Moss, G. P., et al.:** A potential anti-implantation and spermicidal strategy: putative derivatives of nonoxynol-9 and anti-inflammatory agents and their spermicidal activity. *Eur J Contracept Reprod Health Care*, 2007, 11 (4), s. 258–261.
- 39 **Ballagh, S. A. – Baker, J. M. – Henry, D. M., et al.:** Safety of single daily use for one week of C31G HEC gel in women. *Contracept*, 2002, 66 (5), s. 369–375.
- 40 **Witherell, G. W.:** Glyminox Biosyn. *Curr Opin Investig Drugs*, 2004, 5 (2), s. 222–231.
- 41 **Jain, A. – Lal, N. – Kumar, L., et al.:** Novel trichomonocidal spermicides. *Antimicrob Agents Chemother*, 2011, 55 (9), s. 4343–4351.
- 42 **Kumar, L. – Sarswat, A. – Lal, N., et al.:** Imidazole derivatives as possible microbicides with dual protection. *Eur J Med Chem*, 2010, 45 (2), s. 817–824.
- 43 **Batár, I.:** State-of-the-art of non-hormonal methods of contraception: II. Chemical barrier contraception. *Eur J Contracept Reprod Health Care*, 2010, 15 (2), s. 89–95.
- 44 **Driák, D.:** Renaissance spermicidů (?). *Gynekolog*, 2007, 16 (1), s. 20–25.
- 45 **Dvořáčková, K. – Rabišková, M. – Masteiková, R.:** Mikrobicidy v lékových formách. *Remedia*, 2008, 18 (2), s. 181–184.
- 46 **Sitruk-Ware, R. – Variano, B. – Tolenaar, D., et al.:** Vaginal

- hormonal contraception combined with new microbicides: a giant step or a myth? *Eur J Contracept Reprod Health Care*, 2012, 17 (dopl. 1), s. S12–S13.
- 47 **Anderson, R. A.:** Male steroidal contraception. *Eur J Contracept Reprod Health Care*, 2004, 9 (dopl. 1), s. 27.
- 48 **Pasqualotto, F. F. – Lucon, A. M. – Pasqualotto, E. B., et al.:** Trends in male contraception. *Rev Hosp Clin Fac Med Sao Paulo*, 2003, 58 (5), s. 275–283.
- 49 **Merigiola, M. C. – Farley, T. M. – Mbizvo, M. T.:** A review of androgen-progestin regimens for male contraception. *J Androl*, 2003, 24 (4), s. 466–483.
- 50 **Kamischke, A. – Nieschlag, E.:** Progress towards hormonal male contraception. *Trends Pharmacol Sci*, 2004, 25 (1), s. 49–57.
- 51 **Benoff, S. – Cooper, G. W. – Hurley, I., et al.:** The effect of calcium ion channel blockers on sperm fertilization potential. *Fertil Steril*, 1994, 62 (3), s. 606–617.
- 52 **Hershlag, A. – Cooper, G. W. – Benoff, S.:** Pregnancy following discontinuation of a calcium channel blocker in the male partner. *Hum Reprod*, 1995, 10 (3), s. 599–606.
- 53 **Goodwin, L. O. – Leeds, N. B. – Hurley, I., et al.:** Isolation and characterisation of the primary structure of testis-specific L-type calcium channel: implication for contraception. *Mol Hum Reprod*, 1997, 3 (3), s. 255–268.
- 54 **Shi, Y.-L. – Bai, J.-P. – Wang, W. P.:** Ion-channels in human sperm membrane and contraceptive mechanisms of male antifertility compounds derived from Chinese traditional medicine. *Acta Pharmacol Sin*, 2003, 24 (1), s. 22–30.
- 55 **Zhang, D. – Gopalakrishnan, M.:** Sperm ion channels: molecular targets for the next generation of contraceptive medicines? *J Androl*, 2005, 26 (6), s. 643–653.

Kombinovaná léčba hepatitidy C telaprevirem a peginterferonem alfa a ribavirinem

prof. MUDr. Petr Husa, CSc. Klinika infekčních chorob LF Masarykovy univerzity a FN Brno

- 1 **Husa, P.:** Trojkombinační léčba chronické hepatitidy C. *Vnitř Lék*, 2012, 58, s. 588–590.
- 2 **Němeček, V.:** Sérologický přehled ČR v roce 2001 – virová hepatitida A, B, C. *Zprávy CEM*, 2003, 12, s. 55–61.
- 3 **Urbánek, P. – Husa, P. – Galský, J. – Šperl, J. – Hejda, V. – Kümpel, P. – Němeček, V. – Plíšek, S. – Volfová, M.:** Standardní diagnostický a terapeutický postup u chronické infekce virem hepatitidy C (HCV). *Gastroent Hepatol*, 2012, 66, s. 214–229.
- 4 **Jacobson, I. M. – McHutchinson, J. G. – Dusheiko, G. – Di Bisceglie, A. M. – Reddy, K. R. – Bzowej, H. M., et al.:** for ADVANCE Study Team: Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med*, 2011, 364, s. 2405–2416.
- 5 **Sherman, K. E. – Flamm, S. L. – Afdhal, N. H. – Nelson, D. R. – Sulikowski, M. S. – Everson, G. T., et al.:** Telaprevir in combination with peginterferon alfa 2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid virological response: final results of Phase 3 ILLUMINATE study. *Hepatology*, 2010, 52, s. 401A.
- 6 **Zeuzem, S. – Andreone, P. – Pol, S. – Lawitz, E. – Diago, M. – Roberts, S., et al.:** Telaprevir for retreatment of HCV infection. *N Engl J Med*, 2011, 364, s. 2417–2428.

Adherence k léčbě interferonem β -1a

MUDr. Pavel Hradílek, Ph.D. MS centrum, Neurologická klinika FN Ostrava

- 1 **Atkinson, M. J. – Sinha, A. – Hass, S. L., et al.:** Validation of a general measure of treatment satisfaction, The Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. *Health Qual Life Outcomes*, 2004, 2, s. 12.
- 2 **Brandes, D. W. – Callender, T. – Lathi, E., et al.:** A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events. *Curr Med Res Opin*, 2009, 25, s. 77–92.
- 3 **Cohen, B.:** Adherence to disease modifying therapy for multiple sclerosis. *Int J MS Care*, 2006, 8, s. 32–37.
- 4 **Cohen, B. A. – Rieckmann, P.:** Emerging oral therapies for multiple sclerosis. *Int J Clin Pract*, 2007, 61, s. 1922–1930.
- 5 **Cox, D. – Stone, J.:** Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. *J Neurosci Nurs*, 2006, 38, s. 167–171.
- 6 **Cramer, J. A. – Cuffel, B. J. – Divan, V., et al.:** Patient satisfaction with an injection device for multiple sclerosis treatment. *Acta Neurol Scand*, 2006, 113, s. 156–62.
- 7 **Horne, R.:** Compliance, adherence and concordance: implications for asthma treatment. *Chest*, 2006, 130, s. 65–72.
- 8 **Mohr, D. C. – Boudewyn, A. C. – Likosky, W., et al.:** Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self inject. *Ann Behav Med*, 2001, 23, s. 125–132.
- 9 **O'Brien, J. A. – Ward, A. J. – Patrick, A. R.:** Cost of managing an episode of relapse in multiple sclerosis in the United States. *BMC Health Serv Res*, 2003, 3, s. 17.
- 10 **Sabaté, E. (ed.):** *Adherence to long-term therapies: Evidence for action.* Ženeva, Švýcarsko, World Health Organization, 2003.
- 11 **Steinberg, S. C. – Faris, R. J. – Chang, C. F., et al.:** Impact of adherence to interferons in the treatment of multiple sclerosis. A non-experimental, retrospective, cohort study. *Clin Drug Investig*, 2010, 30, s. 89–100.
- 12 **Stone, V. E.:** Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. *Clin Infect Dis*, 2001, 33, s. 865–72.
- 13 **Treadaway, K. – Cutter, G. – Salter, A., et al.:** Factors that influence adherence with disease-modifying therapy in MS. *J Neurol*, 2009, 256, s. 568–576.
- 14 **Tremlett, H. L. – Oger, J.:** Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. *Neurology*, 2003, 6, s. 551–554.

Gilenya, perorální farmakoterapie roztroušené sklerózy

doc. MUDr. Jan Mareš, Ph.D. Centrum pro diagnostiku a léčbu demyelinizačních onemocnění, Neurologická klinika LF UP a FN, Olomouc

- 1 Scott, L. J.: Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis. *CNS Drugs*, 2011, 25 (8), s. 637–698.
- 2 SPC přípravku Fingolimod (Gilenya), SÚKL. Dostupné na www.sukl.cz/file/69716_1_1/.
- 3 Kappos, L. – Radue, E. W. – O'Connor, P. – Polman, C. – Hohlfeld, R. – Calabresi, P. – Selmaj, K. – Agoropoulou, C. – Leyk, M. – Zhang-Auberson, L. – Burtin, P.: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. *The New England Journal of Medicine*, 2010, 362, 5, s. 387–401.
- 4 Cohen, J. A. – Barkhof, F. – Comi, G., et al.: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. *N Engl J Med*, 2010, 362, s. 402–415.
- 5 Šavrdová, E. – Kappos, L. – Cohen, J. A. – Devonshire, V. – Zhang-Auberson, L. – Häring, D. A. – Eckert, B. – Francis, G.: Clinical and magnetic resonance imaging outcomes in subgroups of patients with highly active relapsing-remitting multiple sclerosis treated with fingolimod (FTY720): results from the FREEDOMS and TRANSFORMS phase 3 studies. Poster. *5th Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis*, Amsterdam, Nizozemsko, 19.–22. říjen 2011.
- 6 Brinkmann, V. – Davis, M. D. – Heise, C. E. – Albert, R. – Cottens, S. – Hof, R. – Bruns, C. – Prieschl, E. – Baumruker, T. – Hiestand, P. – Foster, C. A. – Zollinger, M. – Lynch, K. R.: The immune modulator FTY720 targets sphingosine 1-phosphate receptors. *J Biol Chem*, 2002, 277 (24), s. 21453–21457.
- 7 Matloubian, M. – Lo, C. G. – Cinamon, G. – Lesneski, M. J. – Xu, Y. – Brinkmann, V. – Allende, M. L. – Proia, R. L. – Cyster, J. G.: Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. *Nature*, 2004, 427 (6972), s. 355–360.
- 8 Dev, K. K., et al.: Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. *Pharmacol Ther*, 2008, 117, s. 77–93.
- 9 Brinkmann, V.: Sphingosine-1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. *Pharmacol Ther*, 2007, 115, s. 84–105.
- 10 Chun, J. – Hartung, H. P.: Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. *Clin Neuropharmacol*, 2010, 33 (2), s. 91–101.

Léčba hypertenze fixní kombinací amlodipinu a bisoprololu

MUDr. Jiří Slíva, Ph.D. Ústavy farmakologie 2. a 3. LF UK, Praha

- 1 Neutel, J. M.: Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. *Curr Med Res Opin*, 2008, 24, s. 2389–2401.
- 2 Mancía, G. – De, B. G. – Dominiczak, A., et al.: 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J* 2007, 28, s. 1462–1536.
- 3 Mancía, G. – Laurent, S. – Agabiti-Rosei, E., et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. *J Hypertens*, 2009, 27, s. 2121–2158.
- 4 Agabiti-Rosei, E. – Heagerty, A. M. – Rizzoni, D.: Effects of antihypertensive treatment on small artery remodelling. *J Hypertens*, 2009, 27, s. 1107–1114.
- 5 Wang, J. G. – Staessen, J. A. – Li, Y., et al.: Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. *Stroke*, 2006, 37, s. 1933–1940.
- 6 Struijker-Boudier, H. A. – Ambrosioni, E. – Holzgreve, H., et al.: The need for combination antihypertensive therapy to reach target blood pressures: what has been learned from clinical practice and morbidity-mortality trials? *Int J Clin Pract*, 2007, 61, s. 1592–1602.
- 7 Carre, A.: Pharmacologic importance of the combination atenolol/nifedipine in hypertensive patients. *Drugs*, 1998, 56, dopl. 2, s. 23–30.
- 8 Rana, R. – Patil, A.: Efficacy and safety of bisoprolol plus amlodipine fixed-dose combination in essential hypertension. *The Ind Pract*, 2008, 61, s. 225–234.

Octreotid v léčbě průjmů vyvolaných cytostatiky

MUDr. Oldřich Louthan IV. interní klinika, Centrum pro neuroendokrinní nádory, VFN a 1. LF UK, Praha

- 1 Maroun, J. A. – Anthony, L. B. – Blair, H., et al.: Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. *Curr Oncol*, 2007, 14 (1), s. 13–20.
- 2 Kornblau, S. – Benson, A. B. – Catalano, R., et al.: Management of cancer treatment-related diarrhea. Issues and therapeutic strategies. *J Pain Symptom Manage*, 2000, 19 (2), s. 118–129.
- 3 Klener, P. – Vorlíček, J.: *Podpůrná léčba v onkologii*. Galén, 1998, s. 229.
- 4 Farthing, M. J. G.: Antisecretory drugs for diarrheal disease. *Dig Dis*, 2006, 24, s. 47–58.
- 5 Karalis, K. – Mastorakos, G. – Chrousos G. P., et al.: Somatostatin analogues suppress the inflammatory reaction in vivo. *J Clin Invest*, 1994, 93, s. 2000–2006.
- 6 Goumas, P. – Naxakis, S. – Christopoulou, A., et al.: Octreotide acetate in the treatment of fluorouracil-induced diarrhea. *The Oncologist*, 1998, 3, s. 50–53.
- 7 Major, P. – Figueredo, A. – Tandan, V., et al., and members of the Systemic Treatment Disease Site Group Practice Guideline Report 12-7 In Review: *The role of octreotide in the management of patients with cancer care Ontario*.
- 8 Wadler, S. – Haynes, H. – Wiernik, P. H.: Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea. *J Clin Oncol*, 1995, 13, s. 222–226.
- 9 Zidan, J. – Haim, J. – Beny, A. – Stein, M.: Octreotide in the treatment

- of severe chemotherapy-induced diarrhea. *Ann Oncol*, 2001, 12 (2), s. 227–229.
- 10 **Rosenoff, S. H.**: Octreotide LAR resolves severe chemotherapy-induced diarrhoea (CID) and allows continuation of full-dose therapy. *Eur J Cancer Care (Engl)*, 2004, 13 (4), s. 380–383.
- 11 **Rosenoff, S. H. - Gabrail, N. Y. - M. D., Conklin, R., et al.**: A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: Results of the STOP Trial. *J Support Oncol*, 2006, 4, s. 289–294.
- 12 **Zachariah, B. - Clement, K. - Gwede, C.K. - James, J., et al.**: Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: Randomized RT OG Trial 0315. *J Natl Cancer Inst*, 2010, 102, s. 1–10.
- 13 **Högenauer, C. - Aichbichler, B. - Sanat Ana, C. - Porter, J. - Fordtran, J.**: Effect of octreotide on fluid absorption and secretion by the normal human jejunum and ileum in vivo. *Aliment Pharmacol Ther*, 2002, 16, s. 769–777.

Nové možnosti léčby CHOPN selektivním inhibítorem fosfodiesterázy 4 (PDE4) roflumilastem – kazuistika

MUDr. Zuzana Perná Pneumologická ambulance Medicon, a. s., Praha

- 1 **Musil, J.**: Systémové projevy a komorbidita u chronické obstrukční plicní nemoci – nové možnosti léčby. *Med. Praxi*, 2012, 9, s. 278–280.
- 2 **Vondra, V. - Vondrová, I.**: Diferenciální diagnóza a terapie chronické obstrukční plicní nemoci a astmatu. *Interní med*, 2012, 14, s. 350–356.
- 3 **Kašák, V.**: Roflumilast – první perorální inhibitor fosfodiesterázy 4 (PD4 inhib.) uvedený do klinické praxe pro léčbu CHOPN. *Farmakoterapie*, 2012, 8, s. 16–26.
- 4 **Agusti, A. - Soriano, J. B.**: COPD as a systemic disease. *COPD*, 2008, 5, s. 133–138.
- 5 **Rabe, K. F.**: Roflumilast for the treatment of chronic obstructive pulmonary disease. *Expert Rev Resp Med*, 2010, 4, s. 543–555.
- 6 **Calverley, P. M. - Rabe, K. F. - Goehring, U. M., et al.**: Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomized clinical trials. *Lancet*, 2009, 374, s. 685–694.
- 7 **Global strategy for diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD**, 2011, www.goldcopd.org.
- 8 **Hatzelmann, A., et al.**: *Pulmonary Pharm Therapeutics*, 2010, 23, s. 235–256.

Symptomatická léčba Alzheimerovy demence – využití rivastigminu

doc. MUDr. Roman Jiráček, CSc. Psychiatrická klinika 1. LF UK a VFN Praha

- 1 **Chitnis, S. - Rao, J.**: Rivastigmine in Parkinson's disease dementia. *Expert Opin Drug Metab Toxicol*, 2009, 5, s. 941–955.
- 2 **Darreh-Shori, T. - Soinenen, H.**: Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies. *Current Alzheimer Research*, 2010, 7, s. 67–73.
- 3 **Djordjevic, S. - Japalac, S. - Vidojevic, V.**: Effects of rivastigmin tartarate in the therapy of patients with schizophrenia. *Ann Gen Psychiatry*, 2010, 9, s. 91.
- 4 **Emíre, M.**: Dementia in Parkinson's disease: cause and treatment. *Curr Opin Neurol*, 2004, 17, s. 399–404.
- 5 **Frankfurt, S. V. - Appels, B. A. - De Boer, A. - Tulner, L. R. - Van Campen, J. P. - Koks, C. H. - Beijnen, J. H.**: Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting. *Int J Clin Pract*, 2006, 60, s. 646–654.
- 6 **Gauthier, S. - Juby, A. - Dalziel, W. - Réhel, B. - Schecter, R.**: Explore investigators: Effect of rivastigmine on common symptomatology of Alzheimer's disease (EXPLORE). *Curr Med Res Opin*, 2010, 26, s. 1149–1160.
- 7 **Kumar, P. - Kumar, A.**: Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations. *Eur J Pharmacol*, 2009, 615, s. 91–101.
- 8 **McKeith, I. - Del Ser, T. - Spano, P. F. - Emíre, M. - Nesnes, K. - Nand, R. - Ferrari, R. - Spiegel, R.**: Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. *The Lancet*, 2000, 355, s. 2031–2036.
- 9 **Miller, T.**: Rivastigmine in the treatment of patients with Alzheimer's disease. *Neuropsychiatr Dis Treat*, 2007, 3, s. 211–218.
- 10 **Muhlack, S. - Przuntek, H. - Miller, T.**: Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer's disease. *Pharmacopsychiatry*, 2006, 39, s. 16–29.
- 11 **Poewe, W. - Wolters, E. - Emíre, M. - Onofri, M. - Hsu, C. - Tekin, S. - Lane, R.**: EXPRESS investigators: Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. *Mov Disord*, 2006, 21, s. 456–461.
- 12 **Sadowsky, C. H. - Dengiz, A. - Meng, X. - Olin, J. T. - for the US38 Study Group.**: Switching from oral donepezil to rivastigmine transdermal patch in Alzheimer's disease: 20-week extension. *Prim Care Companion J Clin Psychiatry*, 2010, 12, PCC.09m00852.
- 13 **Takeda, A. - Loveman, E. - Clegg, A. - Kirby, J. - Picot, J. - Payne, E. - Green, C.**: A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. *Int J Geriatr Psychiatry*, 2006, 21, s. 17–28.
- 14 **Tiraboschi, P. - Hansen, L. A. - Alford, M. - Sabbagh, M. N. - Schloos, B. - Masliah, E. - Zhal, L. J. - Corey-Bloom, J.**: Cholinergic dysfunction in disease with Lewy bodies. *Neurology*, 2000, 54, 407–411.
- 15 **Vnoučková, K. - Jiráček, R.**: Rivastigminum. *Remedia*, 2003, 13, s. 372–378.

Endometrióza – diagnostika a terapie, nové metody

MUDr. Pavel Tomeš | doc. MUDr. Zdeněk Novotný, CSc.

Gynekologicko-porodnická klinika LF UK a FN Plzeň

- 1 **Abrao, M. S., et al.:** Comparison between clinical examination, transvaginal sonography and magnetic resonance imaging for the diagnosis of deep endometriosis, *Hum Reprod*, 2007, 22, s. 3092–3097.
- 2 **Al-Jefout, M. – Dezarnaulds, G. – Cooper, M. – Tokushige, N. – Luscombe, G. M. – Markham, R. – Fraser, I. S.:** Department of Obstetrics and Gynaecology, Queen Elizabeth II Research Institute for Mothers and Infants, University of Sydney, Sydney, NSW 2006, Australia. drmoamar@yahoo.co.uk. Diagnosis of endometriosis by detection of nerve fibres in an endometrial biopsy: a double blind study. *Hum Reprod*, 2009, 24 (12), s. 3019–3024, Epub 18. 8. 2009.
- 3 **Crosignani, P., et al.:** Advances in the management of endometriosis: an update for clinicians, *Hum Reprod*, 2006, 12, s. 179–189.
- 4 **7, ESHRE guideline for the diagnosis and treatment of endometriosis.** 2007, endometriosis.org
- 5 **Fanta, M.:** Endometrióza. *Česká gynekologie*, 2012, 77, s. 314–319.
- 6 **Fischerová, D.:** Ultrazvukové zobrazení benigních a maligních ovarálních nádorů. In: *Ultrazvuková diagnostika v těhotenství a gynekologii*. Praha, Aprofema, 2010, s. 461–462.
- 7 **Franzoni, F. – Quinones-Galvan, A. – Regoli, F. – Ferrannini, E. – Galletta, F.:** A comparative study of the in vitro antioxidant activity of statins. *Int J Cardiol*, 2003, 90 (2–3), s. 317–321.
- 8 **Hartus, H. A. – Bruner-Tran, K. L. – Zhang, X. – Osteen, K. G. – Lyttle, C. R.:** A selective estrogen receptor-beta agonist causes lesion regression in an experimentally induced model of endometriosis. *Hum Reprod*, 2005, 20 (4), s. 936–941.
- 9 **Hrušková, H.:** Medikamentózní terapie endometriózy. In: *Moderní gynekologie a porodnictví*, Praha, Levret, 2012, 21, 2, s. 192–202.
- 10 **Hsu, A. L. – Khachikyan, I. – Stratton, P.:** Invasive and noninvasive methods for the diagnosis of endometriosis. *Clin Obstet Gynecol*, 2010, 53 (2), s. 413–419.
- 11 **Huang, H. Y.:** Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Taipei, Chang Gung University College of Medicine, Taoyuan, Taiwan. hongyuan@cgmh.org.tw. Medical treatment of endometriosis. *Chang Gung Med J*, 2008, 31 (5), s. 431–440.
- 12 **Chapron, C. – Fauconnier, A. – Vieira, M. – Barakat, H. – Dousset, B. – Pansini, V. – Vacher-Lavenu, M. C. – Dubuisson, J. B.:** Anatomical distribution of deeply infiltrating endometriosis: surgical implications and proposition for a classification. *Hum Reprod*, PubMed PMID: 12525459, 2003, 18 (1), s. 157–161.
- 13 **Balasz, J. – Creus, M. – Fabregues, F. – Carmona, F. – Ordi, J. – Martinez-Roman, S. – Vanrell, J. A.:** Visible and non-visible endometriosis at laparoscopy in fertile and infertile women and in patients with chronic pelvic pain: a prospective study. *Hum Reprod*, 1996, 11 (2), s. 387–391.
- 14 **Kučera, E.:** *Endometrióza*. Praha, Maxdorf, 2008.
- 15 **Kučera, E.:** Současný pohled na chirurgickou léčbu endometriózy. In: *Moderní gynekologie a porodnictví*, Praha, Levret, 2012, 21, 2, s. 207–212.
- 16 **Kučerová, I.:** Endometrióza v ultrazvukovém obraze. In: *Moderní gynekologie a porodnictví*, Praha, Levret, 2012, 21, 2, s. 165–175.
- 17 **Kulak, J. Jr. – Fischer, C. – Komm, B. – Tailor, H. S.:** Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model. In: Kulak, J. Jr. – Fischer, C. – Komm, B. – Taylor H. S.: *Endocrinology*. Epub 17. 5. 2011, 2011, 152 (8), s. 3226–3232.
- 18 **Okaro, E., et al.:** The use of ultrasound-based „soft markers“ for the prediction of pelvic pathology in women with chronic pelvic pain—can we reduce the need for laparoscopy? *BJOG*, 2006, 113, s. 251–256.
- 19 **Panay, N.:** Advances in the medical management of endometriosis, PubMed PMID: 18485157, *BJOG*, 2008, 115 (7), s. 814–817.
- 20 **Taylor, M. M.:** *Endometriosis—a missed malady. Review*. PubMed PMID: 12619848, *AORN J*, 2003, 77 (2), s. 298, 301–309, 312–313.

Reprogramace terminálně diferencovaných buněk

prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

- 1 **Gurdon, J. B.:** Developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpole. *Journal of Embryology and Experimental Morphology*, 1962, 10, s. 622–640.
- 2 **Wilmut, I. – Schnieke, A. E. – McWhir, J. – Kind, A. J. – Campbell, K. H. S.:** Viable offspring derived from fetal and adult mammalian cells. *Nature*, 1997, 385, s. 810–813.
- 3 **Schnieke, A. E. – Kind, A. J. – Ritchie, W. A. – Mycock, A. R. – Scott, A. R. – Ritchie, M. – Wilmut, I. – Colman, A. – Campbell, K. H. S.:** Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts. *Science*, 1997, 278, s. 2130–2133.
- 4 **Schmidt, C.:** Belated approval of first recombinant protein from animal. *Nature Biotechnology*, 2006, 24, s. 877.
- 5 **Kling, J.:** First US approval for a transgenic animal drug. *Nature Biotechnology*, 2009, 27, s. 302–304.
- 6 **Takahashi, K. – Yamanaka, S.:** Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*, 2006, 126, s. 663–676.
- 7 **Takahashi, K. – Tanabe, K. – Ohnuki, M. – Narita, M. – Ichisaka, T. – Tomoda, K. – Yamanaka, S.:** Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell*, 2007, 131, s. 861–872.
- 8 **Qian, L. – Huang, Y. – Spencer, C. J. – Foley, A. – Vedantham, V. – Liu, L. – Conway, S. J. – Fu, J. – Srivastava, D.:** In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. *Nature*, 2012, 485, s. 593–598.
- 9 **Marchetto, M. C. N. – Carromeu, C. – Acab, A. – Yu, D. – Gene, W. – Yeo, G. W. – Mu, Y. – Chen, G. – Gage, F. H. – Muotri, A. R.:** A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. *Cell*, 2010, 143, s. 527–539.
- 10 **Brennan, K. J. – Simone, A. – Jou, J. – Gelboin-Burkhardt, C. – Tran, N. – Sangar, S. – Li, Y. – Mu, Y. – Chen, G. – Yu, D. – McCarthy, S. – Sebat, J. – Gage, F. H.:** Modelling schizophrenia using human induced pluripotent stem cells. *Nature*, 2011, 473, s. 221–225.
- 11 **Israel, M. A. – Yuan, S. H. – Bardy, C. – Reyna, S. M. – Mu, Y. – Herrera, C. – Hefferan, M. P. – Van Gorp, S. – Nazor, K. L. – Boscolo, F. S. – Carson, C. T. – Laurent, L. C. – Marsala, M. – Gage, F. H. – Reme, A. M. – Koo, E. K. – Goldstein, L. S. B.:** Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. *Nature*, 2012, 482, s. 216–220.
- 12 **Itzhaki, I. – Maizels, L. – Huber, I. – Zwi-Dantsis, L. – Caspi, O. – Winterstern, A. – Feldman, O. – Gepstein, A. – Arbel, G. – Hammerman, H. – Boulos, M. – Gepstein, L.:** Modelling the long QT syndrome with induced pluripotent stem cells. *Nature*, 2011, 471, s. 225–229.
- 13 **Koch, P. – Breuer, P. – Peitz, M. – Jungverdorben, J. – Kesavan,**

- J. – Poppe, D. – Doerr, J. – Ladewig, J. – Mertens, J. – Tüting, T. – Hoffmann, P. – Klockgether, T. – Evert, B. O. – Wüllner, U. – Brüstle, O.: Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. *Nature*, 2011, 480, s. 543–546.
- 14 Lee, G. – Papapetrou, E. P. – Kim, H. – Chambers, S. M. – Tomishima, M. J. – Fasano, C. A. – Ganat, Y. M. – Menon, J. – Shimizu, F. – Viale, A. – Tabar, V. – Sadelain, M. – Studer, L.: Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. *Nature*, 2009, 461, s. 402–406.
- 15 Ieda, M. – Fu, J.-D. – Delgado-Olguin, P. – Vedantham, V. – Hayaishi, Y. – Brunea, B. G. – Srivastava, D.: Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. *Cell*, 2010, 142, s. 375–386.
- 16 Song, K. – Nam, Y.-J. – Luo, X. – Qi, X. – Tan, W. – Guo, G. N. – Acharya, A. – Smith, C. L. – Tallquist, M. D. – Neilson, E. G. – Hill, J. A. – Bassey-Duby, R. – Olson, E. N.: Heart repair by reprogramming non-myocytes with cardiac transcription factors. *Nature*, 2012, 485, s. 599–604.
- 17 Pang, Z. P. – Yang, N. – Vierbuchen, T. – Ostermeier, A. – Fuentes, D. R. – Yang, T. Q. – Citri, A. – Sebastiano, V. – Marro, S. – Südhof, T. C. – Wernig, M.: Induction of human neuronal cells by defined transcription factors. *Nature*, 2011, 476, s. 220–223.
- 18 Zhou, Q. – Brown, J. – Kanarek, A. – Rajagopal, J. – Melton, D. A.: In vivo reprogramming of adult pancreatic exocrine cells to β -cells. *Nature*, 2008, 455, s. 627–632.